The Ethics of Deep Brain Stimulation for Treatment-Resistant Psychiatric Disorders

Abstract

Deep brain stimulation has moved beyond movement disorders into an expanding, but still largelyinvestigational, role in treatment- resistant psychiatric illness, most notably obsessive-compulsive disorder and major depression. This review examines the ethical questions that recur across this literature: the difficulty of securing genuinely informed, uncoerced consent from patients who have exhausted every other treatment option, and the possibility that stimulation alters affect, impulsivity, or narrative identity rather than only the target symptom. We also examine what the failure of a major sham-controlled depression trial revealed about equipoise and premature translation in this field, and how the narrow humanitarian device exemption pathway used for obsessive-compulsive disorder sits against the weaker evidentiary base for other indications. Emerging closed-loop, adaptive systems introduce a further layer of concern around continuous physiological data collection and the blurring of agency between patient and device.
We conclude that responsible expansion of psychiatric deep brain stimulation depends on treating uncertainty about mood and identity effects as something to disclose rather than minimize, and on building data-governance and long-term device-stewardship frameworks into trial design now rather than after wider deployment.